Endothelin and active renin levels in essential hypertension and hypertension with renal artery stenosis before and after percutaneous transluminal renal angioplasty by Edwards-Teunissen, K. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/25769
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Original article 1791
Endothelin and active renin levels in essential hypertension 
and hypertension with renal artery stenosis before and after 
percutaneous transluminal renal angioplasty
Kim Edwards Teunissen, Cornelis T. Postma, Brigit C. van Jaarsveld*, 
Frans H.M. Derkx* and Theo Thien
Objective To determine whether active renin and 
endothelin levels in venous plasma differ between 
patients with renal artery stenosis and patients with 
primary hypertension. Among the patients with renal 
artery stenosis we also compared active renin and 
endothelin levels between subjects who had been cured 
or whose blood pressure had Improved after treatment of 
the stenosis and those without a beneficial reaction after 
such treatment.
Methods We measured immunoreactive endothelin and 
active renin levels in peripheral venous plasma before 
and 1 h after angiotensin converting enzyme inhibition in 
25 patients with primary hypertension and in 27 patients 
with hypertension and renal artery stenosis.
Percutaneous transluminal angioplasty was performed in
21 patients of the latter group. For 11 patients of this 
group, hypertension was cured or there was an 
improvement, whereas 10 other patients did not respond 
to this treatment. Baseline active renin and endothelin 
levels were compared between these groups, as were 
the clinical characteristics of the patients.
Results Baseline endothelin levels were similar in 
members of the renal artery stenosis [median 3.6 pg/ml 
(range 1.4-11.7)] and in members of the no stenosis 
group [5.0 pg/ml (1.5-8.0)]. Also baseline endothelin 
levels did not differ between members of the 
successfully treated [3.6 pg/ml (1.8-8.9)] and 
unsuccessfully treated groups [3.75 pg/ml (1.4-8.3)]» 
Angiotensin converting enzyme (ACE) inhibition failed to 
cause a significant change in endothelin level in
members of any of the patient groups. Although baseline 
renin levels differed significantly between members of 
the renal artery stenosis and no stenosis groups 
[40.2 [xu/ml (0.9-543) versus 13.4 piu/ml (2.5-931), 
(P<0.05)]r there was no difference in baseline renin 
levels between the members of successful and 
unsuccessful groups [25.7 jxu/ml (9.2-475.6) versus
65.3 juiu/ml (12.3-542.6)]. ACE inhibition caused a 
significant increase in renin level in members of all 
groups except the unsuccessfully treated group.
Conclusions Circulating endothelin levels did not differ 
significantly among patients with essential hypertension, 
hypertension with renal artery stenosis and proven 
renovascular hypertension and, although the 
renin-angiotensin system was clearly activated in 
members of the renovascular hypertension group, ACE 
inhibition did not affect their endothelin levels. These 
results suggest that endothelin does not play a direct 
role in the pathophysiology of renovascular hypertension.
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Introduction
The endothelins are vasoactive peptides of which up to 
now three different isopeptides have been identified. 
Endothelin-1 (ET-1) is a potent vasoconstrictor produced 
by endothelial cells [1], In the kidney it is produced both 
in endothelial and in non-endothelial cells [2]. No storage 
granules of ET -1 have been discovered thus far and 
approximately 25% of ET -1 synthesized is sccreted into 
the general circulation [3]. Endothelins have been thought 
to have a considerable impact on the vascular tone both 
in normal physiological and in diseased states, How­
ever, plasma endothelin levels have not been found to
be elevated in essential hypertension [4,5]. Endothelin 
levels are elevated in pulmonary hypertension and renal 
failure [5,6]. Because vasoactive substances take such an 
important part in the pathophysiology of renovascular 
hypertension (RVH), it is worth considering whether 
endothelins are involved in at least some of the vascular 
reactivity mechanisms operating in this form of high blood 
pressure.
»
Specific information about the role of endothelin in RVH 
is, however, incomplete. Several findings suggest that 
endothelin could be involved in RVH through involve­
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ment with the renin-angiotensin system. First, endothe­
lial cell culture studies have shown that hypoxia [7] and 
angiotensin II (Ang II) induce synthesis and release of 
endothelin [8]. Angiotensin converting enzyme (AGE) 
inhibition attenuates this release [9], Second, Ang II stim­
ulates endothelial production of endothelin and thereby 
potentiates contractions in response to noradrenaline in 
mesenteric resistance arteries of spontaneously hyper­
tensive rats [10]. Furthermore, Sventek et al. [11] found 
vascular overexpression of ET -1 gene in one-kidney, one 
clip hypertensive rats but only during the late phase of 
two-kidney, one clip hypertensive rats. Also several 
clinical studies have been reported but they produced 
contradictory results in which endothelin levels were 
found to be either normal or elevated in patients with 
renal artery stenosis (RAS) [12-15],
The aim of the present study was to investigate a poss­
ible role of endothelin in the pathophysiology of RVH in 
humans. We studied endothelin and renin levels in 
peripheral venous blood before and after ACE inhibition 
in members of the following groups of hypertensive 
patients: subjects with essential hypertension, persons 
with hypertension and RAS, patients whose hypertension 
was cured or alleviated by percutaneous transluminal renal 
angioplasty (PTRA) treatment of RAS and patients whose 
hypertension was not lessened by PTRA treatment of
RAS.
In studying these specific patient groups, we supposed 
that we would be able to employ AGE inhibition and 
responses to PTRA as tools to select out RAS patients 
with true RVH, allowing us to compare endothelin levels 
of these renovascular hypertensives with those of other 
hypertensives. Given the evidence on endothelin summa­
rized above, we hypothesized that AGE inhibition would 
cause not only an increase in renin levels but also, via a 
decrease in Ang II levels, a decrease in circulating 
endothelin levels in patients with RVH. Furthermore, the 
renin: endothelin level ratio before and after AGE inhi­
bition could provide a reliable marker for distinguishing 
true RVH from essential hypertension cases with and 
without RAS.
mercury sphygmomanometer with the patient supine. 
The mean of three consecutive readings was used. The 
possibility that these patients had other forms of second­
ary hypertension was assessed by determination of serum 
electrolyte levels, plasma renin activity, aldosterone levels 
and catecholamine levels. Urinary excretions of creatinine, 
metanephrines and protein were also measured. Endo­
genous creatinine clearance was calculated from serum 
creatinine level measurements [16], The urine screenings, 
together with microscopy of urine sediments were used 
to exclude the possibility that these patients had 
parenchymatous renal disease. Patients with other forms 
of secondary hypertension and patients with renal in­
sufficiency were excluded from this study. For determi­
nation of plasma concentrations of active renin and 
endothelin, venous blood was collected into tubes 
containing EDTA. Samples were centrifuged immedi­
ately at 0°C and stored at -20°C until assay. Active renin 
and endothelin-1 levels were measured by radioim­
munoassays, as described previously [17,18], The anti­
serum for endothelin-1 exhibited 67% cross-reactivity 
with endothelin-2 and 84% with endothelin-3. PTRA was 
performed as a standard procedure via the femoral 
approach under direct high-resolution fluoroscopy. The 
reactions of blood pressure to the procedure were deter­
mined according to the internationally accepted criteria. 
A patient with blood pressure below 90 mmHg without 
medication was considered cured. Improvement was 
defined as a decline in blood pressure by at least 15% 
with the same medication or a decline by 10% with 
discontinuation of administration of at least one anti­
hypertensive drug. Patients who had been cured and 
patients who had improved were placed in the success­
fully treated group and all patients with other outcomes 
in the unsuccessfully treated group. A stenosis was consid­
ered significant if the vascular lumen was found by angio­
graphy to have narrowed by more than 50%. PTRA was 
performed in patients with RAS for whom there was no 
contra-indication to the treatment and who consented to 
be subjected to the procedure. Patients were adminis­
tered 300 mg acetylsalicylic acid a day starting 1 day 
before the procedure and continuing for 3 months after­
wards.
Patients and methods
For 52 hypertensive patients newly referred to the out­
patient clinic, the physicians in charge deemed it neces­
sary to perform intra-arterial digital subtraction angio­
graphy. Indications for angiography were treatment-resis- 
tant hypertension, defined as blood pressure values above 
160/90 mmHg despite two-drug treatment, and other 
clinical clues suggestive of RAS, such as an abdominal 
bruit and a sudden rise of a known blood pressure.
Clinical and biochemical data of these patients were col­
lected. Blood pressure was measured by using a standard
Statistical analysis
Values are expressed as medians (ranges) unless indicated 
otherwise. Comparisons of the data within groups were 
analysed by Wilcoxon’s paired signed rank test for para­
meters with non Gaussian distributions. Student’s paired 
t test was used for parameters with normal distributions. 
Differences between groups were assessed by unpaired 
tests. When appropriate the Bonferroni correction for 
multiple comparisons was applied. The correlations of 
endothelin levels in members of the RAS, the primary 
hypertension, the successfully treated and the unsuc­
cessfully treated groups either with renin level or with
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endogenous creatinine clearance were analysed by 
Spearman’s rank correlation test. Statistical significance 
was assumed at a 5% level, two-sided.
Results
Of the 52 patients with hypertension who had undergone 
diagnostic digital subtraction angiography, 25 had no RAS 
and were diagnosed as having essential hypertension. The 
remaining 27 patients proved to have RAS. There were 
20 unilateral and seven bilateral cases. The clinical char-
The baseline renin level in members of the RAS group 
was significantly higher than that in members of the
essential hypertension group [40.2 jxu/ml (0.9-543) and
13.4 fxu/ml (2.5-931), respectively, 0.049]. The base­
line level of endothelin did not differ significantly 
between RAS [3.6 pg/ml (1.4-11.7)] and essential hyper­
tension [5.0 pg/ml (1 .5-8.0)] cases.
The baseline renin level in members of the successfully 
treated group [25.7 (xu/rnl (9.2-475.6)] was not signifi­
cantly different from that in members of the unsuccess-
acteristics of the patients with and without RAS are fully treated group [65.3 jxu/ml (12.3-542.6)] and neither
summarized in Table 1. The groups differed only in base- were the baseline endothelin levels [3.6 pg/ml (1 .8-8.9)
line systolic blood pressure, that of the RAS group being and 3.75 pg/ml (1.4-8.3), respectively], 
significantly higher than that of the group without stenosis
[186 mmHg (140-246) versus 168 mmHg (120-215),
P < 0.05]. Furthermore, atherosclerosis was the major aeti- 
ological factor for RAS in our study rather than fibro- 
muscular dysplasia (FMD, 20 versus seven patients).
Twenty-one of the 27 patients with RAS were treated by 
PTRA of the stenosis. O f the 21 patients treated, 11 
exhibited decreases in blood pressure in response to this 
treatment. The remaining 10 patients did not respond to 
this treatment. The clinical characteristics of these
ACE inhibition caused significant rises in active renin 
levels in members both of the RAS and of the essential 
hypertension group, [from 40.2 jxu/ml (1-543) to
98.6 |uuu/ml (3.2-2004); P * 0.001 and from 13.4 fxu/ml 
(2.5-931) to 20.4 |xu/ml (2.9-1432), P = 0.03, respectively]. 
In addition, the RAS patients who responded to treat­
ment by PTRA displayed a significant rise in renin levels 
after ACE inhibition [from 25.7 |mu/ml (9.2-475) to
72.8 ¡xu/rnl (10.4-2004), P= 0.001], whereas members of 
the unsuccessfully treated group failed to respond to ACE
patients are summarized in Table 1. Bilateral RAS was inhibition in terms of a significant rise in renin levels from
found in patients in the unsuccessfully treated group more baseline [from 65.3 [ui/ml (12.3-542.6) to 145 |xu/ml
often than it was in patients in the successfully treated (11.3-1298)]. 
group (four versus one patient). Blood pressures of all
patients with FMD-related RAS responded to PTRA The differences (i.e. after-before values) in renin levels
treatment. Conversely, the unsuccessfully treated group before and after AGE inhibition did not differ significantly
was comprised entirely of patients with RAS as a result between members of the RAS group [47.6 (xuml (—28.5
of atherosclerosis. The five patients with FMD RAS were to 1528) and members of the group with essential hyper-
also the five women in the successfully treated group. 
Thus, although male patients with atherosclerotic RAS 
were distributed evenly between the successfully and 
unsuccessfully treated groups, the female patients with 
atherosclerotic RAS did not respond to treatment by
PTRA.
tension [3.1 jxu/ml (-106 to 500)]. This also held true for 
the successfully treated group [47 jjuuml (-2 to 1528) and 
the unsuccessfully treated group [50 jui/ml (-28 to 847)]. 
The relative differences between baseline values and 
those after ACE inhibition were not significant for any of 
the groups.
Table 1 Clinical characteristics of hypertensive patients with or without renal artery stenosis, successfully 
or unsuccessfully treated by percutaneous transluminal renal angioplasty
No stenosis 
(n =  25)
Renal artery 
stenosis 
(n =  27)
Treatment 
successful 
(n = 11 )
Treatment 
unsuccessful 
(n =  10)
Men/women 13/12 15/12 6/5 6/4
Age (years) 48 (24-63) 52 (29-76) 48 (29-71) 55 (44-76)
Unilateral/bilateral stenosis 20/7 a 10/1 6/4
Aetiology; atherosclerosis/FMD 20/7* - ,___ 6/5f 10/0
Baseline SBP (mmHg) 168 (120-215) 186 (140-246)* 180 (140-210) 197 (158-246)
Baseline DBP (mmHg) 101 (70-120) 108 (90-145) 108 (90-130) 109 (96-145)
BMI (kg/m2) 26.3 (17.8-43.0) 25.1 (17.6-39.6) 26.2 (19,1-30.5) 25.2 (21.6-29.6)
ECC (ml/min) 98.3 (26.4-256.2) 82.3 (23.2-153.3) 89.3 (45-153) 75.0 (32-134)
Smokers/non-smokers 12/13 14/13 7/4 5/5
With/without diabetes mellitus 1/1 1/0 0/0 0/0
Values are expressed as medians (ranges). FMD, fibromuscular dysplasia; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; BMI, body mass index; ECC, endogenous creatinine clearance. *No relation to the seven bilateral RAS patients. +All 
FMD patients were women. <  0.05, versus no stenosis.
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Comparison of circulating endothelin levels in patients with hypertension before and after angiotensin converting enzyme (ACE) inhibition. 
Horizontal bars, medians.
The patients with essential hypertension had a baseline 
endothelin level of 5.0 pg/ml (1.5-8.0) and the subjects 
with RAS had a baseline endothelin level of 3.6 pg/ml 
(1.4-1.7), which values were not significantly different 
(Fig. 1). In members of the successful treatment group 
baseline endothelin level was 3.6 pg/ml (1.8-8.9) and in 
members of the unsuccessful group it was 3.75 pg/ml 
(1.4-8.3); also these values were not significantly different
(Fig. 2).
ACE inhibition caused no significant change in endothelin 
levels in members of any of the four study groups. 
Furthermore, the differences and relative differences in 
endothelin levels before and after ACE inhibition did not 
differ significantly between members of die RAS group 
and the essential hypertension group and between 
members of the successfully and the unsuccessfully 
treated groups.
The renin : endothelin level ratio at baseline was signi­
ficantly higher for the RAS group in comparison with 
that for the essential hypertension group [9.4 jxu/pg 
(0.1-131.5) versus 2.5 pAi/pg (0.4-221.7), respectively, 
P= 0.020]. ACE inhibition further increased the signifi­
cant difference between renin : endothelin level ratios for 
the RAS and essential hypertension groups [26.5 jxu/pg
(0.4-554.2) versus 3.6 (xu/pg (0.5-227.3), respectively 
P « 0.005].
The renin : endothelin level ratio at baseline was the same 
for the group that responded as it was for the group that 
did not respond to treatment by PTRA. Furthermore, 
ACE inhibition failed to cause a significant difference 
between values of this ratio for these patient groups. The 
difference in ratios before and after ACE inhibition did 
not differ significantly between the successfully and 
unsuccessfully treated groups.
Endothelin levels in peripheral venous blood were not 
correlated either to renin levels or to endogenous creati­
nine clearances for all four groups.
Discussion
The results of the present study indicate that endothelin 
levels in peripheral venous blood under baseline resting 
conditions are comparable among patients with essential 
hypertension, hypertension combined with RAS and 
RVH. In addition, ACE inhibition and thus a decrease in 
Ang II levels did not affect endothelin levels in patients 
with essential hypertension, patients with essential hyper­
tension combined with RAS and patients with RVH. 
Although the renin : endothelin level ratio differed signif-
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Comparison of circulating endothelin levels in patients for whom percutaneous transluminal renai angioplasty had been successful and 
unsuccessful at lowering blood pressure before and after angiotensin converting enzyme (ACE). Horizontal bars, medians.
icantly between the groups with and without RAS, this 
was largely, if not completely, due to the significant differ­
ence in renin levels. This argument also applies to the 
renin : endothelin level ratio after ACE inhibition, which 
displayed an even more significant difference.
In dividing the group of patients with RAS into those 
who responded to PTRA and those who did not* we 
attempted to distinguish between RAS leading to RVH 
and RAS occurring concomitantly with essential hyper­
tension. Interestingly, among the patients with RAS, 
administration of the ACE inhibitor caused renin levels 
to rise only in members of the group who responded to 
treatment by PTRA. Therefore, the fact that endothelin 
levels did not differ between these groups and were not 
affected differently by ACE inhibition makes the hypoth­
esis that endothelin plays a role in the pathophysiology 
of RVH less plausible.
It is possible that the production and release of endothelin 
were not affected during the relatively short 60 min 
sampling period used in this study. However, an oral dose 
of captopril reaches its maximum plasma level 1 h after 
ingestion and the maximum blood-pressure-lowering 
affect occurs 60-90 min after ingestion. Thus it can be 
concluded that, 60 min after ingestion, while captopril is 
affecting the renin-angiotensin system and other mechan­
isms involved in regulation of blood pressure, regulation 
of endothelin production seems not to be altered.
Plasma levels of endothelin both in essential hypertension 
and in RVH patients both with and without ACE inhi­
bition have been investigated by several other groups. 
Results of most studies [12-15] concur with the results 
of the present study. Two groups who studied endothelin 
levels in blood samples taken directly from renal arteries 
and veins found endothelin levels in healthy controls, 
patients with essential hypertension and patients with 
RAS to be within the normal range [14,15]. Januszewicz 
et al. [19] reported that the degree of activation of the 
renin-angiotensin system had no effect on the endothelin 
levels, which were also not elevated in their patients with 
RAS. In contrast, Giussani et al. [12] did find an increase 
in plasma endothelin levels in patients with RAS and 
elevated Ang II levels.
Several in-vitro studies with isolated arteries from rats and 
humans have shown that the vasocons trie ting effect of 
infusion of endothelin-1 on vascular smooth muscle cells 
is blunted in subjects with mild forms of hypertension 
[19-21]. Furthermore, vascular smooth muscle cells from 
spontaneous hypertensive rats display lower than normal 
responses of intracellular calcium levels to infusion of 
endothelin-1 but exhibit higher than normal responses to
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infusion of Ang II [22,23]. These results suggest that 
endothelin does not affect vasoreactivity once hyper­
tension has been established and thus possibly this could 
explain why endothelin levels are not elevated in most 
hypertensive (patients with essential hypertension and 
patients with RVH) subjects studied. Possibly endothelin 
plays a role in vasoreactive events leading to chronic 
hypertension. However, Sventek et al. [11] recently 
showed that, although the one-kidney one clip Goldblatt 
hypertensive rat exhibits vascular overexpression of the 
endothelin-1 gene, the two-kidney, one clip Goldblatt 
hypertensive rat only does so during a late phase. This 
late expression could also be linked to renal failure or to 
an inability of the lungs or kidneys to clear the endothelin. 
Thus, although many studies, including the present one, 
could not show that circulating endothelin plays a role in 
maintaining RVH, endothelin’s role in the early phase of 
RVH has yet to be sufficiently studied.
With the exception of baseline systolic blood pressure, 
there were no significant differences among the clinical 
characteristics of the groups studied. Male and female 
patients were distributed equally among groups. In a 
recent study [24] it was found that plasma endothelin 
levels are modulated by the menstrual cycle. Although 
this new knowledge does not directly affect the results 
of the present study, all future studies of this type should 
take the effect of the menstrual cycle on endothelin 
levels into consideration when experimenting on female 
subjects. Of the 27 patients with RAS, seven were diag­
nosed as having bilateral stenosis. Furthermore, four of 
the unsuccessfully and one of the successfully treated 
patients had bilateral RAS. In such cases, both renal 
arteries were treated by PTRA. It was, however, beyond 
the scope of this study to evaluate the difference between 
unilateral and bilateral stenosis with regard to hyper­
tension, renin levels and endothelin levels.
In conclusion, the present study showed that circulating 
levels of endothelin in patients with essential hyper­
tension, patients with hypertension with RAS and patients 
with true RVH are similar. Although the renin- 
angiotensin system in patients with RVH was activated, 
as shown by a significant increase in plasma renin activity 
after AGE inhibition, endothelin levels were not corre­
lated co the renin levels and were not affected by AGE 
inhibition. These results do not support the hypothesis 
that production of endothelin in RVH patients is depen­
dent on Ang II.
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